stockrowLivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.
- Revenue
- +9.88%
- EPS
- +27.4%
- Free cash flow
- −31.0%
- Total debt
- −31.2%
Quarter to September 2026, against a year earlier
Follow LIVN
Alert me
LivaNova PLC (LIVN) EPS (diluted)
LivaNova PLC's EPS (diluted) for fiscal 2025 was −$4.45, compared with $1.16 in fiscal 2024. Over the twelve months to 30 September 2026 it was $3.49. Over the past ten years it has ranged from −$7.10 (fiscal 2020) to $2.17 (fiscal 2015); the current reading is higher than 18% of that period. LivaNova PLC ranks 13th of 147 Medical Devices companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$4.45 | — |
| FY2024 | $1.16 | 262.50% |
| FY2023 | $0.32 | — |
| FY2022 | −$1.61 | — |
| FY2021 | −$2.68 | — |
| FY2020 | −$7.10 | — |
| FY2019 | −$3.21 | — |
| FY2018 | −$3.91 | — |
| FY2017 | −$0.52 | — |
| FY2016 | −$1.29 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.60 | (68.95%) |
| Jun 2026 | $1.93 | 382.50% |
| Mar 2026 | $0.40 | (28.57%) |
| Dec 2025 | $0.56 | 14.29% |
| 45 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| BIO Bio-Rad Laboratories, Inc. compare | $37.97 |
| LIVN LivaNova PLC | $3.49 |
| ITGR Integer Holdings Corporation compare | $2.98 |
| HAE Haemonetics Corporation compare | $2.23 |
| NEOG Neogen Corporation compare | −$0.25 |
| TXG 10x Genomics compare | −$0.59 |
| AXGN AxoGen, Inc. compare | −$0.65 |
| BRKR Bruker Corporation compare | −$1.01 |
| IRTC iRhythm Holdings, Inc. compare | −$1.17 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on LIVN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement